分析师通过购买评级来提升Medline股票, 引用规模和增长潜力, 股票在2026年1月12日开盘时在40.52美元. Analysts boost Medline stock with buy ratings, citing scale and growth potential, as shares open at $40.52 on Jan. 12, 2026.

分析师在Medline(MDLN)上发布了多份公牛评级,包括Jefferies、Wolfe Research和J.P.Morgan等公司指定了“买家”或“超绩效”评级和最高达50美元的价格目标,并引述了该公司250亿美元的供应链规模、主要供应商地位以及扩大利润潜力。 Analysts have issued multiple bullish ratings on Medline (MDLN), with firms including Jefferies, Wolfe Research, and J.P. Morgan assigning "buy" or "outperform" ratings and price targets up to $50.00, citing the company’s $25 billion supply chain scale, prime vendor status, and margin expansion potential. 2026年1月12日,该股票开放40.52美元,为期52周,从34.89美元到45.50美元不等。 The stock opened at $40.52 on January 12, 2026, with a 52-week range of $34.89 to $45.50. 虽然主要股东Hellman & Friedman出售了610万股,但董事Andrew J. While major shareholder Hellman & Friedman sold 6.1 million shares, Director Andrew J. Mills通过购买260万股增加了他的股份。 Mills increased his stake by purchasing 2.6 million shares. 尽管内部活动喜忧参半,但市场情绪仍然积极,尽管一些分析家告诫说,许多乐观情绪可能已经定价。 Despite mixed insider activity, market sentiment remains positive, though some analysts caution that much of the optimism may already be priced in.